New research trials surrounding Retatrutide , specifically the 120mg formulation branded as ZPHC, indicate a considerable impact on physique decrease and associated health factors. Researchers posit that this dual agonist , targeting both GLP-1 and GIP systems, may provide a major improvement in the approach of overweight and related health risks